A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
Gwenaelle Gravis
,
Patricia Marino
,
Daniel Olive
,
Frederique Penault-Llorca
,
Jean-Pierre Delord
,
et al.
Journal articles
hal-04109560v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
Célestin Bigarré
,
François Bertucci
,
Pascal Finetti
,
Gaëtan Macgrogan
,
Xavier Muracciole
,
et al.
Journal articles
hal-04008520v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency
Marie-Christine Etienne-Grimaldi
,
Nicolas Pallet
,
Valérie Boige
,
Joseph Ciccolini
,
Laurent Chouchana
,
et al.
Journal articles
hal-03934173v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Mechanistic modeling of brain metastases in NSCLC provides computational markers for personalized prediction of outcome
Sebastien Benzekry
,
Pirmin Schlicke
,
Pascale Tomasini
,
Eleonore Simon
2023
Preprints, Working Papers, ...
hal-03935739v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Structuration d’un programme de dépistage des cancers du poumon incluant un phénotypage clinique, radiologique et biologique utile au développement d’outils de prédiction individualisée du risque - PREVALUNG ETOILE
David Boulate
,
Dominique Barbolosi
2023
Preprints, Working Papers, ...
hal-03926628v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol
David Boulate
,
Marine Fidelle
,
Caroline Caramella
,
Justin Issard
,
Olivier Planche
,
et al.
Journal articles
hal-03926501v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Therapeutic Drug Monitoring of Biotherapies in oncology: hype or hope
Joseph Ciccolini
PAMM-EORTC 47th Winter Meeting , European Organization for Research and Treatment of Cancer, Dec 2022, Florence, Italy
Conference papers
hal-03939677v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial
Fabrice Barlesi
,
Laurent Greillier
,
Florence Monville
,
C Audigier-Valette
,
S. Martinez
,
et al.
2022 ESMO Immuno-Oncology Congress , Dec 2022, Geneva, Switzerland
Conference papers
hal-03928784v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
C. Vicier
,
N. Isambert
,
C. Cropet
,
M. Hamimed
,
L. Osanno
,
et al.
Journal articles
hal-03923625v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Place des anti-BRAF dans le mCRC BRAF-mut: aspects pharmacologiques
Joseph Ciccolini
Cours St Paul Oncologie Digestive , Dec 2022, Nice, France
Conference papers
hal-03941615v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience
Marie Cantaloube
,
Mohamed Boucekine
,
Anne Balossier
,
Xavier Muracciole
,
Mickael Meyer
,
et al.
Journal articles
hal-03926251v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Elise Timon-David
,
Carla Perez
,
Anne Rodallec
Journal articles
hal-03924533v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients
Céleste Cauvin
,
Laurent Bourguignon
,
Laure Carriat
,
Pauline Ghipponi
,
Abel Mence
,
et al.
Journal articles
hal-03923647v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Model-informed and PK-guided dosing in the era of immunotherapy
Joseph Ciccolini
APSA-ASCEPT Joint Conference 2022 , Australasian Pharmaceutical Science Association and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Nov 2022, Perth, Australia
Conference papers
hal-03934244v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Renal impairment and DPD testing: Watch out for false‐positive results!
Laure Carriat
,
Sylvie Quaranta
,
Caroline Solas
,
Maelle Rony
,
Joseph Ciccolini
Journal articles
hal-03923650v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Anti CDK4/6: aspects pharmacologiques et PK/PD
Joseph Ciccolini
Pfizer Internal Symposium , Nov 2022, Paris, France
Conference papers
hal-03939710v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Pharmacokinetics of intact lipid nanocapsules using new quantitative FRET technique
Vincent Lebreton
,
Norraseth Kaeokhamloed
,
Anastasiia Vasylaki
,
Grégory Hilairet
,
Adélie Mellinger
,
et al.
Journal articles
hal-03804976v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Semi-mechanistic modelling to show the impact of structural modifications on radiolabeled-dendrimers pharmacokinetics
Jessica Ou
,
Béatrice Louis
,
Vincent Nail
,
Laure Balasse
,
Ahlem Bouhlel
,
et al.
DMDG/GMP/SPS , Oct 2022, Amsterdam, Netherlands
Conference papers
hal-03930671v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
Olivier Demaria
,
Laurent Gauthier
,
Marie Vetizou
,
Audrey Blanchard Alvarez
,
Constance Vagne
,
et al.
Journal articles
hal-03925668v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Pharmacometrics of immune checkpoint Inhibitors
Joseph Ciccolini
EuroBioMed Workshop , EuroBiomed, Oct 2022, Marseille (FR), France
Conference papers
hal-03941559v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Cancer nanomedicine - from the bench to the bedside: rise of ADC in oncology
Joseph Ciccolini
European Cost Action Nano2clinics , Oct 2022, Roma, Italy
Conference papers
hal-03941545v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic
Anne Rodallec
,
Cristina Vaghi
,
Joseph Ciccolini
,
Raphaëlle Fanciullino
,
Sebastien Benzekry
Journal articles
hal-03924541v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Nicolas Penel
,
Sylvie Bonvalot
,
André-Michel Bimbai
,
Alexandra Meurgey
,
François Le Loarer
,
et al.
Journal articles
hal-03925659v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LC-MS/MS assay of mAbs in plasma: application in oncology
Joseph Ciccolini
Promise Proteomics Symposium , Sep 2022, Prague, Czech Republic
Conference papers
hal-03939703v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Model Informed Precision Dosing of Biotherapies
Joseph Ciccolini
IATDMCT Congress , Sep 2022, Prague, Czech Republic
Conference papers
hal-03934057v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Stratégies anti-BRAF anti-MEK dans le mélanome: aspects pharmacocinétiques et pharmacodynamiques
Joseph Ciccolini
Journées Horizon Mélanome , Pierre Fabre, Sep 2022, Paris, France
Conference papers
hal-03941572v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
TDM of oral targeted therapies: is it worth it?
Joseph Ciccolini
ESMO , European Society of Medical Oncology, Sep 2022, Paris, France
Conference papers
hal-03939669v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Practical identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma
Arturo Álvarez-Arenas
,
Wilfried Souleyreau
,
Andrea Emanuelli
,
Lindsay S Cooley
,
Jean-Christophe Bernhard
,
et al.
Journal articles
hal-03921339v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer
Thi Khanh Le
,
Chaïma Cherif
,
Kenneth Omabe
,
Clément Paris
,
François Lannes
,
et al.
Journal articles
hal-03770623v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer
Fabrice Barlesi
,
Laure Deyme
,
Diane-Charlotte Imbs
,
Elissa Cousin
,
Mathieu Barbolosi
,
et al.
Journal articles
hal-03923667v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More